Afferent Pharmaceuticals is a clinical-stage biotechnology company and leader in the development of novel drugs for the treatment of a range of debilitating neurogenic disorders. These disorders affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies as well as chronic pain, and who have limited, if any, treatment options. These chronic pathologies arise when certain nerve fibers become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, and sometimes remain chronically sensitized for months and even years.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/09/15 | $55,000,000 | Series C |
Fidelity Management & Research Company Jennison Associates New Leaf Venture Partners Partner Fund Management Redmile Group Tekla Healthcare Investors Tekla Life Science Investors | undisclosed |
